Journal of Cancer Research and Practice

CASE REPORT
Year
: 2022  |  Volume : 9  |  Issue : 2  |  Page : 65--68

Total metabolic regression after everolimus in an adult patient with pseudomyogenic hemangioendothelioma


Derek De-Rui Huang1, Yi-Hua Liao2, Jen-Chieh Lee3, Tom Wei-Wu Chen1 
1 Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
2 Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
3 Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan

Correspondence Address:
Dr. Tom Wei-Wu Chen
Department of Oncology, National Taiwan University Hospital, No.7, Chung Shan S. Rd., Taipei 100225
Taiwan

Pseudomyogenic hemangioendothelioma (PHE) is a rare vascular tumor harboring the pathognomonic SERPINE1-FOSB fusion. Most patients are treated primarily with surgical resection, but some patients require systemic therapy due to multiple metastases at initial presentation or multifocal recurrence after definitive resection. The most optimal treatment strategy for the disease has yet to be clearly defined; however, mammalian target of rapamycin inhibitors show promise-given–reported anecdotal responses from case reports of pediatric patients. We present an adult patient with multifocal PHE who was successfully treated with everolimus with a significant clinical response.


How to cite this article:
Huang DD, Liao YH, Lee JC, Chen TW. Total metabolic regression after everolimus in an adult patient with pseudomyogenic hemangioendothelioma.J Cancer Res Pract 2022;9:65-68


How to cite this URL:
Huang DD, Liao YH, Lee JC, Chen TW. Total metabolic regression after everolimus in an adult patient with pseudomyogenic hemangioendothelioma. J Cancer Res Pract [serial online] 2022 [cited 2022 Nov 29 ];9:65-68
Available from: https://www.ejcrp.org/article.asp?issn=2311-3006;year=2022;volume=9;issue=2;spage=65;epage=68;aulast=Huang;type=0